Trial Profile

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELVN-002 (Primary) ; Trastuzumab emtansine; Trastuzumab-deruxtecan
Indications Advanced breast cancer; Colorectal cancer; HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Proof of concept
Sponsors Enliven Therapeutics

Most Recent Events

29 Jun 2025 Status changed from recruiting to active, no longer recruiting.
06 Jun 2024 Planned number of patients changed from 178 to 198.
14 May 2024 According to an Enliven Therapeutics media release, company expected to include between approximately 60-100 patients across various lines of therapy with significant follow-up.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com